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Background: Clinical use of selective PDE3 inhibitors as cardiotonic agents is limited because of their
chronotropic and lipolytic side effects. In our previous work, we synthesized a new PDE3 inhibitor named MC2
(6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one) which produced a high positive inotropic
action with a negative chronotropic effect. This work was done to evaluate the effects of MC2 on adipocytes and
compare its effects with those of amrinone and cilostamide.
Methods: Preadipocytes were isolated from rat adipose tissue and differentiated to adipocyte in the presence of
cilostamide, amrinone or MC2. Lipolysis and adipogenesis was evaluated by measuring glycerol level and Oil Red
O staining, respectively. Adipocyte proliferation and apoptosis were determined with MTT assay and Annexin V/PI
staining, respectively.
Results: Differentiation to adipocyte was induced by amrinone but not by cilostamide or MC2. Basal and
isoproterenol-stimulated lipolysis significantly increased by cilostamide (p < 0.05). Similarly, amrinone enhanced
the stimulated lipolysis (p < 0.01). On the other hand, MC2 significantly decreased both adipogenesis (p < 0.05)
and stimulated lipolysis (p < 0.001). Also, incubation of differentiated adipocytes with MC2 caused the loss of cell
viability, which was associated with the elevation in apoptotic rate (p < 0.05).
Conclusion: Our data indicate that selective PDE3 inhibitors produce differential effects on adipogenesis and
lipolysis. MC2 has proapoptotic and antilipolytic effects on adipocytes and does not stimulate adipogenesis.
Therefore, in comparison with the clinically available selective PDE3 inhibitors, MC2 has lowest metabolic side
effects and might be a good candidate for treatment of congestive heart failure.
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Cyclic nucleotide phosphodiesterases (PDEs) control the
level of intracellular cAMP and cGMP, and hence play
important roles in cellular signaling pathways. The
PDEs are grouped into 11 families which differ in
their physiochemical properties, substrate specificities,
tissue distributions, and regulatory mechanisms [1]. Among* Correspondence: Shafieer@mums.ac.ir
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unless otherwise stated.them PDE3 has high expression in heart, airway, liver,
pancreas, and adipose tissue and involves in the regulation
of cardiovascular functions, insulin secretion, and lipid
metabolism [2-5]. Selective PDE3 inhibitors have vasodila-
tory, antithrombotic, antiproliferative, bronchodilatory,
anti-inflammatory, and positive inotropic effects [6-8]. A
number of PDE3 inhibitors including cilostamide,
cilostazol, milirinone, and amrinone were developed
to treat patients with heart failure. However, chronic
treatment with these agents was associated with some
life-threatening side effects, arrhythmia in particular
[7-10]. Therefore, designing new PDE3 inhibitors withl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Structure of phosphodiestrase-3 inhibitors amrinone
(IC50 ~ 50 μM), cilostamide (IC50 ~ 0.1 μM) and a new
cilostamide derivative MC2 (IC50 ~ 1 μM).
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is an attractive subject.
In the previous works we synthesized novel analogs of
cilostamide as selective PDE3 inhibitors and evaluated
their cardiac and metabolic properties. One of the test
compounds, named MC2 (6-[4-(4-methylpiperidin-1-yl)-
4-oxobutoxy]-4-methylquinolin-2(1H)-one), produced a
potent inotropic action without unwanted effect on basal
contraction rate [11-14]. Therefore, it may be a candidate
for use as a PDE inhibitor in patients with cardiovascular
diseases.
However, in adipose tissue, PDE3 inhibitors increase
intracellular cAMP level and thereby increases lipolysis
in adipocytes and enhance adipogenesis in preadipocytes
[15,16]. Dysregulation of lipid metabolism in adipose
tissue may cause deleterious consequences in some
pathological conditions such as diabetes mellitus, insulin
resistance, fatty liver, and obesity [17-19]. Therefore, as a
selective PDE3 inhibitor, MC2 is expected to produce some
effects on lipid metabolism which could be a potential risk
factor for clinical adverse effect.
Therefore, in the present work, we evaluated the effects
of MC2 on adipose tissue functions including adipogenesis
and lipolysis, and also on adipocyte viability and apoptosis.
Furthermore, the effects of MC2 were compared with the
effects of amrinone and cilostamide on adipose tissue.
Materials and method
Chemicals and reagents
Isoproterenol, free glycerol reagent, 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid sodium salt (HEPES), 4,
5-Dimethylthiazol-2-yl, 2, 5-diphenyl tetrazolium (MTT),
fatty acid-free bovine serum albumin (BSA), and collagenase
were purchased from Sigma (USA). Dimethyl sulfoxide
(DMSO) and 3-isobutyl-1-methylxanthine (IBMX) were
provided from Fluka (Buchs, Switzerland). Dulbecco’s
modified eagle’s medium (DMEM), fetal bovine serum
(FBS), penicillin/streptomycin, and Annexin V/PI apoptosis
kit were obtained from Invitrogen (USA). Indomethacin,
dexamethasone, and insulin were kindly provided by EXIR
Company (Iran).
The test compound, MC2, was synthesized based on
cilostamide structure by Department of Organic Chemistry,
Mashhad University of Medical Sciences (Mashhad, Iran)
according to the procedure reported by Sadeghian et al.
and its PDE3 inhibitory action was assessed by Bioscience
Company (BPS Bioscience Inc, San Diego, United States)
using PDE assay Kit as described in previous works
[14,20]. Figure 1 shows the IC50 of cilostamide, amrinone,
and MC2 for PDE3. All the phosphodiesterase inhibi-
tors were dissolved in dimethyl sulfoxide (DMSO) at
a final concentration of 0.1% in the medium and
equal amounts of carrier were added to control groups of
the cells.Animals
Adult male Wistar rats with weights of 280–300 g were
obtained from Laboratory Animal House, Mashhad
University of Medical School, Iran. They were housed
under a 12/12 h light/dark daily cycle at 22°C and had
free access to standard foods and water. All experiments
were conducted in accordance with standard ethical
guidelines and approved by the local ethics committee of
Mashhad University of Medical Sciences.
Preadipocyte preparation and culture
The animals were sacrificed under ether anesthesia and
retroperitoneal fat pads were removed immediately and
placed in phosphate-buffered saline (PBS) supplemented
with 100 U/ml penicillin and 100 μg/ml streptomycin in
sterile condition. The tissue was minced into small
pieces and incubated for 40 min in PBS containing
2 mg/ml collagenase at 37°C with mild agitation [21,22].
After centrifuging, the floated adipocytes were discarded
and the stromal cells were suspended in DMEM
medium supplemented with 10% fetal bovine serum,
100 U/ml penicillin and 100 μg/ml streptomycin and
cultured in flask. After passage 3, the cells were
seeded (at a density of 60000 cells/cm2) in 12-well plates.
On next day, adipogenesis was induced by applying
“induction medium” containing DMEM supplemented with
200 nM insulin, 250 μM IBMX, 1 μM dexamethasone,
200 μM indomethacin and 3% FBS. On day 3, the cells were
subsequently cultured in “maintenance medium” (induction
Figure 2 Differentiation of preadipocyte to adipocyte in the presence of (A) IBMX, (B) no PDE inhibitor, (C) amrinone, (D) cilostamide
and (E) MC2. Adipogenesis was induced by 3 days incubation in “induction medium”; DMEM supplemented with 3% fetal bovine serum, 200 nM
insulin, 250 μM of mentioned PDE inhibitors, 1 μM dexamethasone, 200 μM indomethacin. Then, the cells were subsequently cultured for 6 days
in “maintenance medium” (induction medium without phosphodiestrase inhibitors and indomethacin). Magnification: ×100
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the medium was changed every 3 days.
To investigate the effect of PDE inhibitors on adipo-
genesis, IBMX was replaced with the same concentra-
tion of amrinone, cilostamide, or MC2 in the induction
medium during the first three days of incubation. The
cellular triglyceride accumulation was measured as an
index of the adipocyte differentiation in the presence of
PDE3 inhibitors and compared with IBMX.
Oil Red O staining
Oil Red O was used to stain intracellular triglyceride
droplets in differentiated adipocytes. Briefly, the cells
were washed twice with PBS and fixed with 10% formalin
for 30 min. After an additional washing with PBS, the cells
were incubated with Oil Red O solution for 20 min [21,23].
Excess stain was removed by washing with distilled water
and the stained cells were photographed. Lipid and Oil Red
O were extracted using isopropyl alcohol and absorbance
was measured using a spectrophotometer at a wavelength
of 545 nm. The lipid content for each experimental groupis expressed relative to that of IBMX-differentiated cells
(adjusted to 100%).
Determination of triglyceride
To support Oil Red O staining, the level of intracellular
triglyceride (TG) was evaluated in differentiated adipocytes.
Following washing the cells with PBS, intracellular TG was
dissolved in 200 μl of 1% Triton X-100/PBS solution. Then,
the level of TG was determined by TG assay kit (Pars azma,
Co., Ltd., Iran). The protein concentrations were also
measured by Bio-Rad protein assay dye reagent (Bio-Rad
Laboratories, Inc.). Then the level of TG was normalized to
cellular protein content of each treatment group [24]. The
TG/protein content (mg/mg) was expressed as percentage
compared to IBMX treated group as a control.
Cell proliferation assay
To investigate the effects of the PDE inhibitors on adipo-
cyte proliferation, preadipocytes were seeded (104 cell/well)
in flat-bottomed 96-well culture plates. After differentiation,
adipocytes were incubated with amrinone, cilostamide and
Figure 3 Effects of phosphodiestrase inhibitors on adipogenesis.
Differentiation of preadipocytes was induced by 3 days incubation in
induction medium; DMEM supplemented with 3% fetal bovine serum,
200 nM insulin, 1 μM dexamethasone, 200 μM indomethacin and
250 μM phosphodiestrase inhibitors (IBMX, amrinone (AMR),
cilostamide (CIL), and (MC2 ). Then, the cells were subsequently
cultured for 6 days in “maintenance medium” (induction medium
without PDE inhibitors and indomethacin). Lipid accumulation was
estimated by measuring the optical density (OD) of Oil Red O stain
(A) or the level of triglyceride (TG) eluted from adipocytes (B). Data are
mean ± SEM of three independent experiments performed in triplicate.
*p < 0.05,**p < 0.01 and ***p < 0.001 vs control (IBMX).
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for 6, 12 and 24 h. After completion of the treatment, the
cells were incubated with MTT solution for 3 h at 37°C.
The supernatants were aspirated, DMSO was added to each
well, and the plates were agitated to dissolve the crystal
product [25-27]. Absorbance was measured at 545 nm
(630 nm as a reference) using a StatFAX303 plate reader.
Annexin V/PI double staining analysis
To detect the apoptosis induced by PDE inhibitors,
Annexin V/PI double staining and flow cytometry analysis
were used [28]. After adipocyte differentiation in 12-well
plates, the cells were exposed to 10, 100 and 500 μM of
MC2 for 24 h. After treatment, the cells were washed
twice with cold PBS and resuspended in 100 μl binding
buffer at a concentration of 1 × 106 cells/ml. Then, 5 μl
Annexin V-FITC and 10 μl PI (1 mg/ml) were added to
these cells according to manufacturer’s instructions.
Finally, the cells were analyzed with a FACScalibur
flow cytometer (Becton Dickinson) and the distribution of
normal, apoptotic and necrotic cells was calculated using
WinMDI 2.7 software.
Lipolysis assay
The differentiated adipocytes (cultured in 12-well culture
plates) were pre-incubated with serum-free DMEM for
3 h and then bathed with 1 ml Krebs-Ringer bicarbonate
buffer containing 5.5 mM glucose, 25 mM HEPES
and 2% (w/v) bovine serum albumin. The cells were
left untreated (basal lipolysis) or treated with iso-
proterenol (stimulated lipolysis) and incubated in the
absence or presence of PDE inhibitors at 37°C in a
humidified chamber under constant shaking for 2 h.
Glycerol release in the medium was measured as
index of lipolysis using the free glycerol determination
kit [29,30].
Statistical analysis
The results are presented as the mean ± standard error.
The values were compared using the one-way analysis of
variances followed by Dunnett’s post hoc test. The results
were considered to be statistically significant, if the p-value
was less than 0.05.
Results
Effect of PDE inhibitors on adipogenesis
The absence of IBMX in culture medium significantly
decreased preadipocyte differentiation to adipocyte
comparing to the control medium containing IBMX.
Also, the level of adipogenesis in cilostamide and MC2
containing medium was lower than that of control
medium. However, the effect of amrinone on preadipocyte
differentiation was more than cilostamide and MC2, close
to that of IBMX (Figure 2).Oil Red O staining showed that in the presence of
cilostamide and MC2 the level of lipid droplet accumula-
tion was 69 ± 6% and 46 ± 4%, respectively, which was
significantly lower than control medium containing IBMX
(100 ± 4%, p < 0.01-p < 0.001) (Figure 3A). These findings
were confirmed by measurement of intracellular TG in the
differentiated adipocytes. As shown in Figure 3B, the level
of intracellular TG in the presence of cilostamide (78 ± 6,
P < 0.05) and MC2 (43 ± 5, P < 0.001) was lower than
that of IBMX treated cells (100 ± 10).
Effect of PDE inhibitors on adipocyte proliferation
Incubation of differentiated adipocytes with 10–500 μM
of cilostamide, 10–500 μM of amrinoe and 10–100 μM
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and 24 h (Figure 4). MC2 at 500 μM significantly de-
creased proliferation of differentiated adipocyte to 86 ± 6
(p < 0.05), 82 ± 3 (p < 0.01) and 79 ± 6 (p < 0.01) after 6,
12 and 24 h, respectively.
Effect of MC2 on adipocyte apoptosis
Figure 5A shows the results of bivariate Annexin V/PI
flow cytometry of differentiated adipocyte after 24 h in-
cubation with MC2. The lower left quadrant of the his-
tograms shows the viable cells, which exclude PI and are
negative for FITC-Annexin V binding. The upper right
quadrant represents the early apoptotic cells, which are
PI negative and Annexin V positive, indicating integrity
of the cytoplasmic membrane. The lower right quadrant
represents the non-viable necrotic and late-stage apop-
totic cells, which are positive for Annexin V binding and
PI uptake. As shown in Figure 5B, incubation of differ-
entiated adipocytes with MC2 caused the loss of cell via-
bility at concentrations of 100 μM (p < 0.05) and 500 μM
(p < 0.05). This effect was associated with the elevation
in the number of apoptotic (concentrations of 10 and
100 μM, p < 0.05) and necrotic (concentrations of
500 μM, p < 0.01) cells.
Effect of PDE inhibitors on lipolysis
The differentiated adipocytes were incubated with differ-
ent concentrations of PDE inhibitors and glycerol release
was measured as index of lipolysis. Amrinone at 100 μMFigure 4 Effects of phosphodiestrase inhibitors on viability of differen
concentrations of amrinone (A), cilostamide (B) and MC2 (C) for 6, 12 or 2
are mean ± SEM (n = 9). *p < 0.05 and **p < 0.01 vs control cells (0 μM).significantly increased isoproterenol-induced (but not
basal) lipolysis (p < 0.05). Cilostamide at concentration
of 100 μM significantly increased basal lipolysis from
100 ± 7% to 334 ± 24% (p < 0.001) and also enhanced
stimulated lipolysis from 375 ± 48% to 668 ± 34% (p <
0.01) (Figure 6A). At the concentration of 10 and
100 μM, basal lipolysis was not changed by MC2. How-
ever, it significantly decreased isoproterenol-induced lip-
olysis from 374 ± 48 to 225 ± 27% (p < 0.01) at 100 μM
(Figure 6B).
Discussion
The PDEs play an important role in endocrine and car-
diovascular functions, cell proliferation, cell differenti-
ation, inflammation, and oxidative stress. Therapeutic
application of PDE inhibitors, therefore, ranges from
heart failure to pulmonary diseases to erectile dysfunc-
tion [31,32]. However, clinical application of these agents
is limited because of their side effects, such as
arrhythmia, impaired insulin secretion, and alterations in
lipid metabolism [4,7]. Therefore, synthesis of new PDE3
inhibitors with desired pharmacological properties and
lesser side effects is of great interest. In our previous
work, we synthesized MC2 as a new cilostamide deriva-
tive and showed that it has inotropic action without un-
wanted effect on contraction rate [11,13]. In the present
work, to assess the effect of synthesized compound on
lipid metabolism, we investigated its effects on adipose
tissue functions. Our data showed that MC2 unliketiated adipocytes. The cells were incubated with various
4 h. Cell viability was detected using MTT colorimetric assay. Values
Figure 5 Effect of MC2 on apoptosis of adipocyte. (A) Detection of apoptosis and necrosis assessed with annexin-V-FITC and PI staining. The
cells were treated with the indicated concentration of MC2 for 24 h. (B) Column bar graph of mean cell florescence for Annexin V-/PI- (Viable cells),
Annexin V+/PI- (apoptotic cells), Annexin V+/PI+ (necrotic cells). Data are mean ± SEM of three experiments. *p < 0.05 and **p < 0.01 vs control.
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and lipolysis and even has antilipolytic effect.
In agreement with previous reports, in our study the
PDE3 inhibitors amrinone and cilostamide potentiated
both basal and catecholamine (isoproterenol)-stimulated
glycerol release from adipocyte [33]. However, MC2 not
only did not increase lipolysis, but inhibited catecholamine-
induced glycerol release. Previously, in an in-vitro study we
showed that MC2 increases liver glycogen storage inrat and mouse which was different from those of
other PDE inhibitors [12]. These effects of MC2 cannot be
explained with its PDE3 inhibitory action because PDE
inhibitors enhance lipolysis via elevation of intracellular
cAMP [2].
In our previous studies we found that different PDE3
inhibitors produce differential cardiac and metabolic
effects. All of test compounds produced positive inotropic
effect but with different efficacies, which were not
Figure 6 Effects of phosphodiestrase inhibitors on basal and isoproterenol (ISO)-induced lipolysis. Differentiated adipocytes were
incubated with 100 μM amrinone (AMR), 100 μM cilostamide (CIL) (A) or indicated concentration of MC2 (B) for 120 min. Glycerol release in the
culture media was assayed as lipolysis indicator. Data are mean ± SEM of three experiments. *P < 0.05 and ***P < 0.001 vs Control; #p < 0.05 and
##p < 0.01 vs ISO treated cells.
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they modified atrial contraction rates differently and
some of which produced a negative chronotropic
effect in spite of having a high positive inotropic
effects [11]. Also, in rat hyperglycemic clamp model
MC2 increased insulin secretion similar to the other
tested PDE inhibitors, but opposite to others it
increased the level of glycogen in the liver [12].
These effects implicate that a cAMP-independent
signaling pathways may be involved in the biological
effects of PDE inhibitors which is manifested by MC2 and
may mediate its antilipolytic effect.In patients with poorly controlled diabetes, deficiency
of insulin in conjunction with catecholamine- and
glucagon-stimulated lipolysis enhances fatty acid delivery
to liver which may lead to ketoacidosis and even death
[19]. It is reasonable to conclude that MC2 can decrease
the risk of ketoacidosis through inhibition of lipolysis in
diabetic patients who are candidate to PDE inhibitor
therapy due to cardiovascular diseases.
Consistent with previous reports on the role of PDE
inhibitors in adipogenesis [16,34], we found that deprivation
of differentiation medium from IBMX attenuated adipogen-
esis. Neither cilostamide nor MC2 could restore the level of
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has been revealed that PDEs exist in two forms: soluble
(cytosolic) and particulate (membrane-associated) [35].
It is generally accepted that inhibition of soluble but
not particulate PDE activity is responsible for IBMX-
stimulated differentiation of pre-adipocytes [36]. Therefore,
inhibition of PDE3 which predominately exist in the form
of particulate cannot mimic the role of IBMX in adipocyte
differentiation. On the other hand, similar to what
happens in the heart and kidney [37], amrinone, in high
concentration may inhibit soluble PDE and therefore
could induce adipocyte differentiation approximately to
the level induced by IBMX.
The mass of adipose tissue is determined by size and
number of adipocytes. The size of adipocytes is reduced
by lipolysis and increased by lipogenesis [38,39].
Number of adipocytes is directly related to the rate of
adipogenesis and inversely related to the rate of apoptosis.
Results of Annexin V/PI and MTT assays showed that
MC2 increases adipocyte apoptosis. However, this effect
was produced at high concentrations which reduced
cell viability and proliferation. Since MC2 cannot
increase adipogenesis, its potential proapoptotic effect
may reduce total adipocytes number in fat tissue.
However, antilipolytic effect of MC2 may prevent severe
alteration in the mass of adipose tissue. Future works are
needed to address long term effect of MC2 on fat mass.
In conclusion, our data showed that different types of
PDE3 inhibitors induce different effects on lipolysis
and adipogenesis. Here we introduced MC2 as a new
PDE3 inhibitor with potential proapoptotic and antili-
polytic effects on adipocytes and without stimulatory
action on adipogenesis. These effects of MC2 impli-
cate that, in comparison with amrinone or milrinone,
this drug may have lowest metabolic side effect and
might be a good candidate for treatment of congestive
heart failure.
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